US 2023/0399323 A1Published application

NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF

AssigneesNational Institutes for Quantum Science and Technology, Eisai R&D Management Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited

InventorsMakoto Higuchi, Maiko Ono, Meiei Cho, Takeshi Yamamoto, Takeshi Wakabayashi

Life of this patent

Estimating the term…

Abstract

An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.

Claims10

Dependent claims

A compound represented by the following formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.

Dependencies are inferred from the claim text.

Facts

Application: 18/022,800Filed 24 Aug 2021
Priority: JP 2020-14208025 Aug 2020
Published: 14 Dec 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00
C07D 417/06
Containing two hetero rings: linked by a carbon chain containing only aliphatic carbon atoms
A61K 49/0021
Characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules: the fluorescent group being a small organic molecule
A61K 51/0459
Having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins: having six-membered rings with two nitrogen atoms as the only ring hetero…

Family

US 12,630,544 B2Related patent
US 2023/0399323 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results